Analysts predict that The Medicines Company (NASDAQ:MDCO) will post $20.38 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for The Medicines’ earnings. The lowest sales estimate is $16.52 million and the highest is $26.80 million. The Medicines posted sales of $25.20 million in the same quarter last year, which indicates a negative year-over-year growth rate of 19.1%. The business is expected to report its next earnings results on Tuesday, February 27th.
On average, analysts expect that The Medicines will report full-year sales of $20.38 million for the current fiscal year, with estimates ranging from $76.35 million to $86.70 million. For the next year, analysts forecast that the business will report sales of $63.70 million per share, with estimates ranging from $23.96 million to $124.40 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for The Medicines.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.37) by $0.95. The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $26.06 million. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The firm’s revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) earnings per share.
In other The Medicines news, CEO Clive Meanwell sold 136,250 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $27.24, for a total transaction of $3,711,450.00. Following the sale, the chief executive officer now directly owns 587,652 shares of the company’s stock, valued at $16,007,640.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Fredric N. Eshelman acquired 200,000 shares of the firm’s stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $26.56 per share, for a total transaction of $5,312,000.00. Following the completion of the purchase, the insider now directly owns 1,028,383 shares of the company’s stock, valued at approximately $27,313,852.48. The disclosure for this purchase can be found here. Insiders own 8.22% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. FMR LLC grew its stake in The Medicines by 1.1% during the second quarter. FMR LLC now owns 10,825,038 shares of the company’s stock worth $411,460,000 after buying an additional 117,982 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of The Medicines by 21.9% during the third quarter. Westfield Capital Management Co. LP now owns 2,476,778 shares of the company’s stock worth $91,740,000 after purchasing an additional 445,419 shares in the last quarter. State Street Corp lifted its position in shares of The Medicines by 9.0% during the second quarter. State Street Corp now owns 2,220,199 shares of the company’s stock worth $84,391,000 after purchasing an additional 183,086 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of The Medicines by 24.1% during the second quarter. Franklin Resources Inc. now owns 1,765,169 shares of the company’s stock worth $67,093,000 after purchasing an additional 343,160 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of The Medicines by 1.6% during the second quarter. Alliancebernstein L.P. now owns 1,213,668 shares of the company’s stock worth $46,132,000 after purchasing an additional 19,043 shares in the last quarter.
Shares of The Medicines (MDCO) traded down $1.06 on Monday, hitting $26.08. 231,294 shares of the stock were exchanged, compared to its average volume of 1,230,000. The firm has a market capitalization of $1,900.00, a price-to-earnings ratio of -2.85 and a beta of 0.71. The company has a debt-to-equity ratio of 3.42, a current ratio of 2.31 and a quick ratio of 1.79. The Medicines has a 1-year low of $25.40 and a 1-year high of $55.95.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.